Lilly's Jaypirca met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica
U.S. FDA approves expanded indication for Lilly's Jaypirca , the first and only non-covalent BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Lilly to present data from two positive Phase 3 studies of Jaypirca in chronic lymphocytic leukemia at the 2025 American Society of Hematology Annual Meeting
Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's 'Changing the Thread Collection'
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
